Department of Neurology, University of Ulm, RKU, Oberer Eselsberg 45, 89081 Ulm, Germany.
Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorferstrasse 65, 88397 Biberach, Germany.
Drug Discov Today. 2021 Feb;26(2):429-441. doi: 10.1016/j.drudis.2020.11.023. Epub 2020 Nov 26.
Even though the treatment options and survival of patients with glioblastoma multiforme (GBM), the most common type of malignant glioma, have improved over the past decade, there is still a high unmet medical need to develop novel therapies. Complexity in pathology and therapy require biomarkers to characterize tumors, to define malignant and active areas, to assess disease prognosis, and to quantify and monitor therapy response. While conventional magnetic resonance imaging (MRI) techniques have improved these assessments, limitations remain. In this review, we evaluate the role of various non-invasive biomarkers based on advanced structural and functional MRI techniques in the context of GBM drug development over the past 5 years.
尽管过去十年间胶质母细胞瘤（GBM）——最常见的恶性神经胶质瘤——的治疗选择和患者生存率有所提高，但仍存在着高度未满足的医疗需求，需要开发新的治疗方法。病理和治疗的复杂性需要生物标志物来对肿瘤进行特征描述，定义恶性和活跃区域，评估疾病预后，并对治疗反应进行量化和监测。虽然常规磁共振成像（MRI）技术已经改进了这些评估，但仍存在局限性。在本综述中，我们评估了过去 5 年来基于先进结构和功能 MRI 技术的各种非侵入性生物标志物在 GBM 药物开发中的作用。
